TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03757182

Intervention type: OTHER
Intervention: Wearable activity monitor
Description: Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
Study: NCT03979586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser-assisted hyaluronic acid delivery
Description: The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
Study: NCT04583592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
Study: NCT01988194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
Study: NCT03872908

Intervention type: DEVICE
Intervention: Chilled gloves
Description: Chilled glove for non-dominant hand (patients treated with paclitaxel)

Intervention type: DEVICE
Intervention: Surgical gloves
Description: Surgical gloves (patients treated with oxaliplatine)

Intervention type: DEVICE
Intervention: Surgical gloves
Description: Surgical gloves (patients treated with oxaliplatine)
Study: NCT00611780

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: tube voltage
Description: standard 120 kV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tube voltage
Description: reduced voltage of 100 kV
Study: NCT00293605

Intervention type: PROCEDURE
Intervention: Total Hip Replacement
Description: Implantation of one of 3 stem designs

Intervention type: PROCEDURE
Intervention: Total Hip Replacement
Description: Implantation of one of 3 stem designs

Intervention type: PROCEDURE
Intervention: Total Hip Replacement
Description: Implantation of one of 3 stem designs
Study: NCT04358822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: The umbilical cord will be clamped after specific time intervals
Study: NCT02665793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose DBPCFC to peanut butter
Description: Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose DBPCFC to peanut butter
Description: Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
Study: NCT01431079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine acceptability
Description: One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine acceptability
Description: One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
Study: NCT03119870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Train
Description: Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
Study: NCT02401269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT01140425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00232798
Description: 600 mg oral solution once daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00232798
Description: 300 mg oral solution once daily x 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution once daily x 7 days
Study: NCT02108132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular therapy
Description: bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cellular therapy
Description: Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
Study: NCT02328170

Intervention type: OTHER
Intervention: EUROIMMUN Allergy
Description: Immunoblot assay

Intervention type: OTHER
Intervention: ImmunoCap
Description: Fluoroallergosorbent test
Study: NCT01166074

Intervention type: BIOLOGICAL
Intervention: Subcutaneous IgG (SCIG)
Description: Administered according to normal clinical practice
Study: NCT02395536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: office setting
Description: An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers

Intervention type: OTHER
Group type: OTHER
Intervention: hosptial setting
Description: A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
Study: NCT01140425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg tablet single dose
Study: NCT03153319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection [Humira]
Description: Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection [Humira]
Description: Investigational Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: Placebo Comparator
Study: NCT01266642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo HF-WBI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo CF-WBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo HF-WBI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02401269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01266642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo HF-WBI
Study: NCT02720666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
Study: NCT02185196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 20,000 IU vitamin D3 in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Study: NCT04126512

Intervention type: OTHER
Intervention: PDA ligation
Description: PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.

Intervention type: OTHER
Intervention: PDA ligation
Description: PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
Study: NCT00327704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin
Description: albumin 20% 100 ml/8 hours for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 100 ml/8hours for 3 days
Study: NCT02410811

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: CMR is obtained on all participants in all arms/groups

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: CMR is obtained on all participants in all arms/groups
Study: NCT01266642

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Undergo CF-WBI
Study: NCT04876482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: oral appliance
Description: It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: using continuous positive airway pressure
Description: The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: losing weights
Description: The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: oropharyngeal rehabilitation
Description: OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
Study: NCT00353366

Intervention type: BIOLOGICAL
Intervention: Rotarix
Description: Two doses of the oral vaccine

Intervention type: OTHER
Intervention: Data collection
Description: Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
Study: NCT03296228

Intervention type: RADIATION
Intervention: Flexibility Radiographs (supine, supine side-bend, FB)
Description: Supine, supine side-bend, fulcrum bend
Study: NCT01130077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A2 restricted glioma antigen peptides vaccine
Description: Vaccine given every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Vaccine given every 3 weeks
Study: NCT02141438

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
Study: NCT01970280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study: NCT01649999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01568255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol therapy at 50,000IU for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo at 50,000IU for 8 weeks
Study: NCT02837666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with Spirulina maxima
Description: Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
Study: NCT03296228

Intervention type: RADIATION
Intervention: Flexibility Radiographs (awake traction)
Description: awake traction

Intervention type: RADIATION
Intervention: Flexibility Radiographs (STUGA)
Description: supine traction under GA
Study: NCT02453295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
Study: NCT01109316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro 2 day reservoir in-use
Description: Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro 6 day reservoir in-use
Description: Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
Study: NCT01109316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart 6 day reservoir in-use
Description: Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
Study: NCT02837666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Washout
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Washout
Description: 2 weeks washout period to each study subject to avoid any possible carryover effect.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with placebo
Description: Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with placebo
Description: Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isoenergetic diet
Description: All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
Study: NCT03042338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CET: Central Executive Training
Description: CET: Central Executive Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CET: Comparison Executive Training
Description: CET: Comparison Executive Training
Study: NCT01569074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 75mg twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 50mg twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 12 weeks
Study: NCT03459066

Intervention type: DIAGNOSTIC_TEST
Intervention: Institution-Group
Description: The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life.

Intervention type: DIAGNOSTIC_TEST
Intervention: Institution-Group
Description: The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life.

Intervention type: DIAGNOSTIC_TEST
Intervention: Institution-Group
Description: The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life.
Study: NCT03521674

Intervention type: DEVICE
Group type: OTHER
Intervention: pregnancy termination
Description: Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done

Intervention type: DEVICE
Group type: OTHER
Intervention: pregnancy termination
Description: Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done